Project Grant R03HL178876
Award Date 8/1/25
Completion Date 7/31/27
Dollars Obligated $235K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Georgia, USA
Similar Awards
- This Project Grant award of $395,314 from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) to The Leland Stanford Junior University aims to define the key cellular components and early immunologic events that mediate factor VIII immunity in persons with hemophilia A. The research will investigate the role of type 2 conventional dendritic cells (CDC2) in the development of anti-factor VIII antibodies, with the long-term goal of developing targeted...
- This Project Grant award of $470,553 from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) supports research at Emory University to investigate the genetic regulation of factor VIII inhibitor development in hemophilia A patients. The research aims to elucidate the mechanisms driving immunity to factor VIII replacement therapy, which can lead to the development of neutralizing antibodies that render the treatment ineffective. Using...
- This Project Grant, awarded by the National Heart, Lung, and Blood Institute (CFDA Program 93.837 Cardiovascular Diseases Research), provides $787,021 to The Leland Stanford Junior University (Stanford University) from September 20, 2025 through June 30, 2030. The grant supports research aimed at understanding the mechanisms of Factor VIII inhibitor formation in persons with hemophilia A, with the long-term goal of developing targeted therapies to prevent inhibitor development during early...
- This Project Grant award of $636,982.00 was provided by the National Heart, Lung, and Blood Institute under the Cardiovascular Diseases Research federal grant program (CFDA 93.837). The grant supports research to comprehensively investigate the proteolytic mechanisms that govern factor VIII regulation before and after activation, which is critical for maintaining normal blood clotting and preventing bleeding disorders like hemophilia A. The project aims to understand how proteolysis of factor...
- This Project Grant award, provided by the National Heart, Lung, and Blood Institute under the Cardiovascular Diseases Research program (CFDA 93.837), aims to investigate a novel biotherapeutic immunocytokine (F5111-IC) for suppressing inhibitor formation in hemophilia patients. The total award amount is $1,165,276, with a project period from January 1, 2025 to November 30, 2026. The primary services under this award involve preclinical assessments of the F5111-IC treatment platform to validate...
- This $888,836 Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports research by The Children's Hospital of Philadelphia (CHOP) to develop gene therapy approaches for treating hemophilia A. The key objectives are to: 1) Target factor VIII expression to liver sinusoidal endothelial cells (LSECs) rather than hepatocytes using genome editing and AAV gene addition methods, and 2) Compare the biological effects of expressing...
- This $601,677 Project Grant award from the National Heart, Lung, and Blood Institute's Cardiovascular Diseases Research program (CFDA 93.837) will support a multi-scale study of the mechanisms underlying vaccine-induced immune thrombotic thrombocytopenia (VITT). The University of Massachusetts will conduct experimental and modeling research to characterize the formation of platelet-activating immune complexes and thrombus development triggered by adenoviral-vectored vaccines. The research aims...
- This federal Project Grant award of $110,635.00 from the National Heart Lung and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) aims to characterize how red blood cell aggregation and membrane deformability affect endothelial cell injury and microvascular thrombosis in sepsis patients. The project will use microfluidics assays to analyze patient blood samples and apply machine learning to determine the impact of rheology on clinical outcomes. The research will also assess the...
- This Project Grant award of $248,999.00 from the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports research at Emory University to investigate the molecular mechanisms underlying the context-specific functions of RUNX transcription factors in directing hematopoietic (blood) cell identity. The research aims to determine how RUNX factors dynamically regulate distinct gene programs during early T cell development and megakaryocyte differentiation, as...
- The National Heart, Lung, and Blood Institute, under the Cardiovascular Diseases Research federal grant program (CFDA 93.837), awarded a $391,250.00 Project Grant to Emory University to investigate the role of fibrinogen as a mediator of COVID-19-associated coagulopathy. The award, effective from March 1, 2025 to February 29, 2028, will support a series of experiments testing the hypothesis that elevated fibrinogen levels contribute to the severe coagulation issues observed in critical...